Journal of Thrombosis and Thrombolysis

, Volume 35, Issue 3, pp 387–390 | Cite as

Monitoring target specific anticoagulants

Article

Abstract

New, target specific, oral anticoagulants have been shown to be safe and effective in prevention and treatment of thromboembolism without laboratory monitoring. However, clinical use of the drugs dabigatran, rivaroxaban, and apixaban requires laboratory measurement of their anticoagulant effect in specific clinical situations. This paper reviews the data available on use of screening and specialized testing to measure the anticoagulant effect and drug levels in patients prescribed these medications. Their effect on other coagulation assays is also reviewed.

Keywords

Dabigatran Rivaroxaban Apixaban Coagulation testing Monitoring 

References

  1. 1.
    Garcia D, Libby E, Crowther MA (2010) The new oral anticoagulants. Blood 115:15–20PubMedCrossRefGoogle Scholar
  2. 2.
    Davie EW, Ratnoff OD (1964) Waterfall sequence for intrinsic blood clotting. Science 145:1310–1312PubMedCrossRefGoogle Scholar
  3. 3.
    Hoffman M, Monroe DM (2007) Coagulation 2006: a modern view of hemostasis. Hematol Oncol Clin North Am 21:1–11CrossRefGoogle Scholar
  4. 4.
    Kubitza D, Becka M, Voith B, Zuehlsdorf M, Wensing G (2005) Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor—after multiple dosing in healthy male subjects. Clin Pharmacol Ther 78:412–421PubMedCrossRefGoogle Scholar
  5. 5.
    Raghavean N, Frost CE, Yu Z et al (2009) Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos 37:74–81CrossRefGoogle Scholar
  6. 6.
    Stangier J, Rathgen K, Stahle H, Gansser D, Roth W (2007) The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in male subjects. Br J Clin Pharmacol 64:292–303PubMedCrossRefGoogle Scholar
  7. 7.
    Samama MM, Martinoli JL, LeFlem L, Guinet C, Plu-Bureau G, Depasse F, Perzborn E (2010) Assessment of laboratory assays to measure rivaroxaban—an oral, direct factor Xa inhibitor. Thromb Haemost 103:815–825PubMedCrossRefGoogle Scholar
  8. 8.
    Hillarp A, Baghaei F, Blixter IF et al (2011) Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays. J Thromb Haemost 9:133–139PubMedCrossRefGoogle Scholar
  9. 9.
    Baglin T, Keeling D, Kitchen S (2012) Effects on routine coagulation screens and assessment of anticoagulant intensity in patients taking oral dabigatran or rivaroxaban: guidance from the British Committee for Standard in Haematology. Br J Haematol 159:427–429PubMedCrossRefGoogle Scholar
  10. 10.
    Lindahl TL, Baghaei F, Blixter IF et al (2011) Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays. Thromb Haemost 105:371–378PubMedCrossRefGoogle Scholar
  11. 11.
    van Ryn J, Stangier J, Haertter S, Liesenfeld KH, Wienen W, Feuring M, Clemens A (2010) Dabigatran etexilate—a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 103:1116–1127PubMedCrossRefGoogle Scholar
  12. 12.
    Love JE, Ferrell C, Chandler WL (2007) Monitoring direct thrombin inhibitors with a plasma diluted thrombin time. Thromb Haemost 98:234–242PubMedGoogle Scholar
  13. 13.
    Stangier J, Feuring M (2012) Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran. Blood Coagul Fibrinolysis 23:138–143PubMedCrossRefGoogle Scholar
  14. 14.
    Nowak G (2004) The ecarin clotting time, a universal method to quantify direct thrombin inhibitors. Pathophysiol Haemost Thromb 33:173–183CrossRefGoogle Scholar
  15. 15.
    Pengo V, Crippa L, Falanga A et al (2011) Questions and answers on the use of dabigatran and perspectives on the use of other new oral anticoagulants in patients with atrial fibrillation. A consensus document of the Italian Federation of Thrombosis Centers (FCSA). Thromb Haemost 106:868–876PubMedCrossRefGoogle Scholar
  16. 16.
    Barrett YC, Wang ZQ, Frost C, Shenker A (2010) Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay. Thromb Haemost 104:1263–1271PubMedCrossRefGoogle Scholar
  17. 17.
    Samama MM, Contant G, Spiro TE et al (2012) Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls. Thromb Haemost 107:379–387PubMedCrossRefGoogle Scholar
  18. 18.
    Harenberg J, Marx S, Weiss C, Kramer R, Samama M, Schulman S (2012) Report of the subcommittee of control of anticoagulation on the determination of the anticoagulant effects of rivaroxaban. J Thromb Haemost 10:1433–1436PubMedCrossRefGoogle Scholar
  19. 19.
    Korte W, Jovic R, Hollenstein M, Degiacomi P, Gautschi M, Ferrandez A (2010) The uncalibrated prothrombinase-induced clotting time test. Equally convenient but more precise than the aPTT for monitoring of unfractionated heparin. Hamostaseologie 30:212–216PubMedGoogle Scholar
  20. 20.
    Harenberg J, Kraemer S, Du S, Giese C, Kraemer R (2012) Point of care method for the determination of dabigatran in urine samples from patients on treatment. American Society of Hematology Meeting Abstract #2270, San DiegoGoogle Scholar
  21. 21.
    Funk DMA (2012) Coagulation assays and anticoagulant monitoring. Hematology 2012:460–465PubMedGoogle Scholar
  22. 22.
    Tichelaar V, de Jong H, Nijland H, Kluin-Nelemans H, Meijer K, Mulder A (2011) Interference of rivaroxaban in one-stage and chromogenic factor VIII:C assays. Thromb Haemost 106:990–992PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Hemostasis Reference LaboratoryClinical and Translational Research, Puget Sound Blood Center, University of Washington School of MedicineSeattleUSA

Personalised recommendations